Related Experiment Video

Updated: May 6, 2026

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection
04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

5.5K

Cost-effectiveness of viral hepatitis B & C treatment

Mehlika Toy1

  • 1Department of Global Health and Population, Harvard School of Public Health, Harvard University, Boston, USA.

Best Practice & Research. Clinical Gastroenterology
|November 5, 2013
PubMed

Insights

Effective antiviral therapies for chronic hepatitis B (CHB) and C (CHC) are cost-effective. Health policy decisions benefit from understanding the costs and outcomes of HBV and HCV treatments.

Area of Science:

  • Hepatology
  • Health Economics
  • Public Health

Background:

  • Effective antiviral therapies are available for chronic hepatitis B (CHB) and chronic hepatitis C (CHC).
  • Cost-effectiveness studies are crucial for informing health policy regarding HBV and HCV treatments.
  • Treatment of active CHB is widely accepted as cost-effective compared to no treatment.

Purpose of the Study:

  • To provide insights into recent treatment advancements for CHB and CHC.
  • To analyze cost-effectiveness issues associated with HBV and HCV therapies.
  • To offer an overview of recent cost-effectiveness studies on HBV and HCV treatment.

Main Methods:

  • Review of recent literature on antiviral therapies for CHB and CHC.
  • Analysis of cost-effectiveness studies related to HBV and HCV treatment options.
  • Synthesis of data on treatment outcomes and associated costs.

Main Results:

  • Treatment for active CHB is considered cost-effective.
  • New developments in CHC treatment and diagnostics necessitate cost-benefit analyses.
  • Understanding costs and effects of treatment choices is vital for clinicians and policymakers.

Conclusions:

  • Antiviral therapies for chronic viral hepatitis B and C offer cost-effective solutions.
  • Ongoing evaluation of treatment costs and outcomes is essential for optimizing patient care and health policy.
  • Informed decision-making regarding HBV and HCV management requires consideration of both clinical efficacy and economic impact.

Keywords:
Cost-effectivenessHepatitis BHepatitis CTreatment

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.6K

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
99
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
28
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
73
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
43.1K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
275
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
108